Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADCY1 | Q08828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8712264 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL30352942 | 1.00 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL30988430 | 0.96 | PI4KA (0.92) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL675830 | 0.96 | PI4KA (0.92) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL14908001 | 0.84 | PI4KA (0.72) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL14983401 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL1998927 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL5740769 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| SCHEMBL191944 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBNFKB1 | |
| Methane SCHEMBL10551641 | 0.82 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025110928-A1 | COMPOUNDS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-05-30 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-118121550-A | Drug-loaded microsphere, preparation method thereof and fiber with bionic liver lobule structure prepared by using microsphere | 成都市第一人民医院 | 2024-06-04 | — | — | CN | claimed |
| CN-118068003-A | Application of drug intervention target for treating and/or relieving traumatic inflammation | 上海长征医院 | 2024-05-24 | — | — | CN | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| CN-112888432-A | Methods for delaying the onset of new onset type 2 diabetes and for slowing the progression of type 2 diabetes and treating type 2 diabetes | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 2021-06-01 | — | — | CN | claimed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-20090264383-A1 | Inhibitor of Adenylyl Cyclase for Treating a Disorder of the Circadian Rhythm | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-22 | — | — | US | claimed |
| EP-2023921-A1 | INHIBITOR OF ADENYLYL CYCLASE FOR TREATING A DISORDER OF THE CIRCADIAN RHYTHM | Medical Research Council (GB) | 2009-02-18 | — | — | EP | claimed |
| US-7482134-B2 | Signals and molecular species involved in senescence | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-01-27 | — | — | US | claimed |
| WO-2007135387-A1 | INHIBITOR OF ADENYLYL CYCLASE FOR TREATING A DISORDER OF THE CIRCADIAN RHYTHM | MEDICAL RESEARCH COUNCIL (GB) | 2007-11-29 | — | — | WO | claimed |
| US-20060127370-A1 | Composition for culturing multipotent stem cells and utilization of the same | RIKEN (JP) | 2006-06-15 | — | — | US | claimed |
| US-20060099568-A1 | Signals and molecular species involved in senescence | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2006-05-11 | — | — | US | claimed |
| EP-1557461-A1 | COMPOSITION FOR CULTURING MULTIPOTENT STEM CELLS AND UTILIZATION OF THE SAME | RIKEN (JP) | 2005-07-27 | — | — | EP | claimed |
| EP-1542687-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004028538-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2004-04-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | MMP1, MMP3, MMP10 | PI4KA 3289/4885PI4K2B 3828/4885PI4K2A 3370/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | PI4KA 3777/4885PI4K2B 3928/4885PI4K2A 3419/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | PI4KA 1708/4885PI4K2B 1647/4885PI4K2A 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.